United States Short Bowel Syndrome Market Insights Forecasts to 2033

• The Market is Growing at a CAGR of 8.9% from 2023 to 2033
• The U.S. Short Bowel Syndrome Market Size is Expected to Hold a Significant Share by 2033

The U.S. Short Bowel Syndrome Market Size is Anticipated to Hold a Significant Share by 2033, Growing at a CAGR of 8.9% from 2023 to 2033.

Market Overview

Short bowel syndrome is a complex gastrointestinal disorder that involves the inadequate functional length of the small intestine, usually as the direct result of surgical resection or congenital conditions. This significantly impairs the ability of the body to absorb both nutrients and fluids, with a range of related symptoms and potential nutritional deficiencies associated with the syndrome. Some of the common indications of this syndrome include severe diarrhea, malnutrition, dehydration, electrolyte imbalances, weight loss, and fatigue. Additionally, patients with the disease will also suffer from abdominal cramps, bloating, and an increased sensitivity to complications such as infections and kidney stones because of poor nutrient absorption. Diagnosis of short bowel syndrome is usually based on a medical history review, clinical evaluation, physical examination, and a variety of laboratory investigations. Imaging studies like X-rays, CT scans, and endoscopy can be conducted to determine the amount of intestine left with its functionality.

Report Coverage

This research report categorizes the market for the US short bowel syndrome market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States short bowel syndrome market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the U.S. short bowel syndrome market.

Driving Factors

GLP-2 drug penetration is estimated to rise during the forecast period in the United States. This is owing to the diverse benefits that pipeline candidates are expected to offer, including more frequent dosing and hospitalizations, among others. This syndrome is on the rise in the U.S., therefore, there is a growing demand for developing new drugs to treat this ailment. The statistics released by Crohn's & Colitis Foundation indicate that there are approximately 10,000 to 20,000 patients with this disease in the U.S.

Restraining Factors

The overall cost of treatment with this syndrome is high, and parenteral nutrition is the most common procedure applied for this treatment. The huge cost of drug acquisition annually to treat this condition limits its adoption in the market.

Market Segmentation

The US short bowel syndrome market share is classified into type and application.

• The GLP-2 segment is expected to hold a significant market share through the forecast period.

The United States short bowel syndrome market is segmented by type into GLP-2, growth hormone, and glutamine. Among these, the GLP-2 segment is expected to hold a significant market share through the forecast period. This is attributed to a broad spectrum of GLP-2-based pipeline products for SBS. Furthermore, approved products already available in the market also support the growth of this segment.

• The hospital pharmacies segment is expected to dominate the US market during the projected period.

Based on the distribution channel, the United States short bowel syndrome market is divided into hospital pharmacies and online & retail pharmacies. Among these, the hospital pharmacies segment is expected to dominate the US short bowel syndrome market during the projected period. This is attributed to the cases of SBS-causing diseases, such as Crohn's disease, are on the rise, and the market is on the gaining spree with regard to the need for advanced medicines for such treatments. The key players focus on supplying medicines to hospital pharmacies as the demand increases.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States short bowel syndrome market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Company Limited
• OxThera
• ZEALAND PHARMA
• Ironwood
• Hanmi Pharm Co., Ltd.
• Jaguar Health
• Merck KGaA
• EnteraBio Ltd.
• Nestlé
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States short bowel syndrome market based on the below-mentioned segments:

United States Short Bowel Syndrome Market, By Type

• GLP-2
• Growth Hormone
• Glutamine

United States Short Bowel Syndrome Market, By Distribution Channel

• Hospital Pharmacies
• Online & Retail Pharmacies